ReviewStem cells and development2014
All roads lead to induced pluripotent stem cells: the technologies of iPSC generation.
Review in Stem cells and development, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 103 citations in OpenAlex.
- BRD2 impedes iPSC reprogramming by regulating lipid biosynthesis and the matrisome via its ET tail.Communications biology · 2026Article
- Characteristics of the Stem Cell Intellectual Property Rights and Patent Status: Focusing on Papers and Clinical Trials.Development & reproduction · 2026Article
- Induced Pluripotent Stem Cells in Birds: Opportunities and Challenges for Science and Agriculture.Veterinary sciences · 2024Review
- Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies.International journal of surgery (London, England) · 2024Review
- High-throughput methods for cardiac cellular electrophysiology studies: the road to personalized medicine.American journal of physiology. Heart and circulatory physiology · 2024Review
- Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine.Current medicinal chemistry · 2024Review
- Advanced therapy to cure diabetes: mission impossible is now possible?Frontiers in cell and developmental biology · 2024Review
- The occurrence and development of induced pluripotent stem cells.Frontiers in genetics · 2024Review
- The E1a Adenoviral Gene Upregulates the Yamanaka Factors to Induce Partial Cellular Reprogramming.Cells · 2023Article
- Recent progress in the manipulation of biochemical and biophysical cues for engineering functional tissues.Bioengineering & translational medicine · 2023Review
- Review
- Article
- Stem cell-derived retinal pigment epithelium cell therapy: Past and future directions.Frontiers in cell and developmental biology · 2023Review
- Role of angiogenic transdifferentiation in vascular recovery.Frontiers in cardiovascular medicine · 2023Review
- Dental applications of induced pluripotent stem cells and their derivatives.The Japanese dental science review · 2022Review
- Translational potential of hiPSCs in predictive modeling of heart development and disease.Birth defects research · 2022Review
- miRNA-mediated control of exogenousMolecular therapy. Methods & clinical development · 2022Article
- Review
- Cellular reprogramming and epigenetic rejuvenation.Clinical epigenetics · 2021Review
- Robust Expression of Functional NMDA Receptors in Human Induced Pluripotent Stem Cell-Derived Neuronal Cultures Using an Accelerated Protocol.Frontiers in molecular neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generation of induced pluripotent stem cells (iPSCs) via the ectopic expression of reprogramming factors is a simple, advanced, yet often perplexing technology due to low efficiency, slow kinetics, and the use of numerous distinct systems for factor delivery. Scientists have used almost all available approaches for the delivery of reprogramming factors. Even the well-established retroviral vectors confuse some scientists due to different tropisms in use. The canonical virus-based reprogramming poses many problems, including insertional mutagenesis, residual expression and re-activation of reprogramming factors, uncontrolled silencing of transgenes, apoptosis, cell senescence, and strong immunogenicity. To eliminate or alleviate these problems, scientists have tried various other approaches for factor delivery and transgene removal. These include transient transfection, nonintegrating viral vectors, Cre-loxP excision of transgenes, excisable transposon, protein transduction, RNA transfection, microRNA transfection, RNA virion, RNA replicon, nonintegrating replicating episomal plasmids, minicircles, polycistron, and preintegration of inducible reprogramming factors. These alternative approaches have their own limitations. Even iPSCs generated with RNA approaches should be screened for possible transgene insertions mediated by active endogenous retroviruses in the human genome. Even experienced researchers may encounter difficulty in selecting and using these different technologies. This survey presents overviews of iPSC technologies with the intention to provide a quick yet comprehensive reference for both new and experienced reprogrammers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.